CG Oncology reports positive trial results for bladder cancer therapy

May 15, 2026 8:00 AM

CG Oncology Inc. (NASDAQ: CGON) announced positive results from its CORE-008 Cohort CX Phase 2 trial evaluating an intravesical combination ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found